Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Podrobná bibliografie
Hlavní autoři:	Jadersten, M, Pellagatti, A, Forsblom, A, Emanuelsson, E, Merup, M, Samuelsson, J, Wainscoat, J, Boultwood, J, Hellstorm-Lindberg, E
Médium:	Conference item
Vydáno:	2005

Podobné jednotky

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
Autor: Pellagatti, A, a další
Vydáno: (2006)

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Autor: Pellagatti, A, a další
Vydáno: (2007)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
Autor: Jädersten, M, a další
Vydáno: (2009)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
Autor: Scharenberg, C, a další
Vydáno: (2011)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
Autor: Martin Jädersten, a další
Vydáno: (2009-12-01)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
Autor: Pellagatti, A, a další
Vydáno: (2011)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
Autor: Pellagatti, A, a další
Vydáno: (2011)

Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion
Autor: Martin Jädersten
Vydáno: (2010-03-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
Autor: Nikpour, M, a další
Vydáno: (2007)

Gene expression profiling in the myelodysplastic syndromes.
Autor: Pellagatti, A, a další
Vydáno: (2005)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Autor: Raza Azra, a další
Vydáno: (2012-04-01)

Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion.
Autor: Lewis, S, a další
Vydáno: (1995)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
Autor: Pellagatti, A, a další
Vydáno: (2009)

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion
Autor: Maria Ximeri, a další
Vydáno: (2010-03-01)

The impact of spliceosome mutations in MDS
Autor: Jacqueline Boultwood, a další
Vydáno: (2019-06-01)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
Autor: Pellagatti, A, a další
Vydáno: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
Autor: Pellagatti, A, a další
Vydáno: (2010)

5q- syndrome.
Autor: Boultwood, J, a další
Vydáno: (2012)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
Autor: Pellagatti, A, a další
Vydáno: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
Autor: Pellagatti, A, a další
Vydáno: (2010)

Clonality in the myelodysplastic syndromes.
Autor: Boultwood, J, a další
Vydáno: (2001)

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
Autor: Caceres, G, a další
Vydáno: (2013)

Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide
Autor: Gudrun Göhring, a další
Vydáno: (2011-02-01)

The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.
Autor: Nilsson, L, a další
Vydáno: (2007)

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)
Autor: Axel Rüfer, a další
Vydáno: (2022-07-01)

Molecular pathogenesis of the myelodysplastic syndromes
Autor: Boultwood, J, a další
Vydáno: (1999)

Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide
Autor: Virginie Eclache, a další
Vydáno: (2008-02-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
Autor: Pellagatti, A, a další
Vydáno: (2003)

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
Autor: Pellagatti, A, a další
Vydáno: (2009)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
Autor: Botezatu, L, a další
Vydáno: (2016)

Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide
Autor: Bagi Jana, a další
Vydáno: (2014-01-01)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
Autor: Pellagatti, A, a další
Vydáno: (2005)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
Autor: Boultwood, J, a další
Vydáno: (2012)

Telomere length in myelodysplastic syndromes.
Autor: Boultwood, J, a další
Vydáno: (1995)

Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)
Autor: Pellagati, A, a další
Vydáno: (2008)

Advances in the 5q- syndrome.
Autor: Boultwood, J, a další
Vydáno: (2010)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q).
Autor: Pellagatti, A, a další
Vydáno: (2004)

The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells
Autor: Brigitte Mohr, a další
Vydáno: (2009-03-01)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
Autor: Yu Han Koh, a další
Vydáno: (2023-08-01)

PP2A: The Achilles Heal in MDS with 5q Deletion
Autor: David eSallman, a další
Vydáno: (2014-09-01)